Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene

The latest drug development news and highlights from our US FDA Performance Tracker.

Regeneron Gets A Win With Eylea Approval In Diabetic Retinopathy

Regeneron's workhorse blockbuster Eylea has scored another indication for diabetic retinopathy, as the company braces for new competition from Novartis later this year.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel